www.ijarp.com ISSN 2456-9992 Page: 01-12

International Journal Advanced Research Publications

Review Article

Volume: 02
Issue: 08

BIOFILM FORMATION AND ANTIBIOTIC RESISTANCE IN *STAPHYLOCOCCUS AUREUS*: CURRENT PERSPECTIVES ON PATHOGENESIS, ANTIMICROBIAL RESISTANCE, AND THERAPEUTIC STRATEGIES

Harpreet Kaur*[1], Dr. Manita Paneri[2], Saba Saleha[2], Gurpreet Singh[3]

[1]*Department of Paramedical Sciences, Faculty of Health and Allied Sciences, Guru Kashi University.*

[2]*Assistant Professor, Faculty of Allied and Healthcare, Guru Kashi University.*

[3]*Assistant Professor, Department of Allied & Healthcare Sciences, Guru Kashi University.*

Article Received: 27 June 2026, Article Revised: 17 July 2026, Published on: 04 August 2026

***Corresponding Author: Harpreet Kaur**

Department of Paramedical Sciences, Faculty of Health and Allied Sciences, Guru Kashi University.

Doi: https://doi-doi.org/101555/ijarp.4785

ABSTRACT

Staphylococcus aureus is one of the most significant bacterial pathogens responsible for a wide spectrum of community-acquired and healthcare-associated infections. Its remarkable ability to form biofilms and develop resistance to multiple antimicrobial agents has become a major public health concern worldwide. Biofilms are highly organized microbial communities enclosed within a self-produced extracellular polymeric matrix that protects bacterial cells from antibiotics, host immune responses, and environmental stress. Consequently, biofilm-associated infections are often persistent, difficult to eradicate, and associated with recurrent infections and increased healthcare costs. The emergence of methicillin-resistant *Staphylococcus aureus* (MRSA), vancomycin-intermediate *S. aureus* (VISA), and multidrug-resistant strains has further complicated therapeutic management. This review summarizes current knowledge regarding the molecular mechanisms of biofilm formation, major virulence determinants, antimicrobial resistance mechanisms, laboratory diagnostic approaches, and recent advances in antibiofilm therapies. Particular emphasis is placed on the interaction between biofilm development and antibiotic resistance, which significantly contributes to treatment failure. Recent evidence suggests that effective management requires a combination of rapid laboratory diagnosis, antimicrobial stewardship,

novel therapeutic agents, and biofilm-targeted treatment strategies. Continued research into quorum sensing inhibitors, bacteriophage therapy, antimicrobial peptides, nanotechnology, and biofilm-dispersing enzymes offers promising opportunities for improving clinical outcomes and combating antimicrobial resistance.

KEYWORDS: *Staphylococcus aureus*, Biofilm, Antibiotic resistance, MRSA, Antimicrobial stewardship, Virulence factors, Biofilm-associated infection.

1. INTRODUCTION

Staphylococcus aureus is a Gram-positive, catalase-positive, coagulase-positive bacterium that colonizes approximately 30% of healthy individuals and is recognized as one of the most important opportunistic pathogens in clinical medicine. It causes a broad spectrum of infections ranging from superficial skin and soft tissue infections to life-threatening conditions such as bacteremia, infective endocarditis, pneumonia, osteomyelitis, septic arthritis, and device-associated infections. The organism has become particularly challenging because of its remarkable adaptability, acquisition of antimicrobial resistance genes, and ability to survive under adverse environmental conditions.

One of the defining characteristics of *S. aureus* is its capacity to form **biofilms**, structured microbial communities embedded within an extracellular polymeric substance (EPS). Biofilm formation enables bacterial cells to firmly adhere to host tissues and implanted medical devices, including prosthetic joints, vascular catheters, urinary catheters, orthopedic implants, and cardiac valves. Once established, biofilms create a protective microenvironment that markedly reduces antibiotic penetration and shields bacteria from host immune defenses, making infections chronic and difficult to eradicate. The thesis specifically emphasizes biofilms as an important bacterial survival strategy and discusses their medical significance, mechanisms of formation, and antibiofilm approaches.

The increasing prevalence of multidrug-resistant *S. aureus*, particularly methicillin-resistant *Staphylococcus aureus* (MRSA), has further complicated treatment. Resistance is mediated through multiple mechanisms including acquisition of the **mecA** gene encoding altered penicillin-binding protein (PBP2a), production of β-lactamases, biofilm-associated tolerance, and regulation of efflux pumps. These mechanisms reduce the effectiveness of conventional antibiotics, increase hospital stays, and contribute substantially to morbidity, mortality, and healthcare costs.

Healthcare-associated infections involving biofilm-producing *S. aureus* are especially

problematic because bacterial cells embedded within biofilms may exhibit antibiotic tolerance many hundreds of times greater than planktonic cells. Consequently, conventional antimicrobial therapy alone frequently fails, often necessitating removal of infected prosthetic devices in addition to prolonged antibiotic treatment.

The thesis also highlights modern molecular biology approaches—including DNA isolation, polymerase chain reaction (PCR), cloning, protein expression, and electrophoretic analysis—to investigate biofilm-associated proteins and molecular mechanisms involved in *Staphylococcus* pathogenicity. These advanced laboratory techniques provide valuable insight into bacterial genetics and the development of novel antibiofilm strategies.

This review critically evaluates the current understanding of biofilm biology in *Staphylococcus aureus*, summarizes mechanisms of antimicrobial resistance, discusses laboratory diagnostic approaches, and reviews emerging therapeutic strategies aimed at preventing and treating biofilm-associated infections.

2. Biology and Clinical Importance of *Staphylococcus aureus*

Staphylococcus aureus belongs to the family **Staphylococcaceae** and is characterized by its spherical morphology, Gram-positive cell wall, facultative anaerobic metabolism, and tendency to form grape-like clusters. It naturally colonizes the anterior nares, skin, and mucosal surfaces of healthy individuals while remaining capable of causing opportunistic infections whenever host immune defenses are compromised.

The pathogenicity of *S. aureus* depends upon numerous virulence determinants including adhesins, cytotoxins, hemolysins, leukocidins, proteases, lipases, and immune-evasion proteins. Surface proteins known as microbial surface components recognizing adhesive matrix molecules (MSCRAMMs) facilitate bacterial attachment to extracellular matrix proteins such as fibronectin, fibrinogen, collagen, and elastin. These adhesins initiate colonization and represent the first stage of biofilm formation.

Healthcare-associated infections caused by *S. aureus* remain a major concern worldwide. Patients admitted to intensive care units, surgical wards, dialysis centers, and long-term healthcare facilities experience particularly high infection rates because of frequent exposure to invasive procedures and implanted medical devices. Catheter-associated bloodstream infections, prosthetic joint infections, orthopedic implant infections, chronic wound infections, diabetic foot ulcers, and infective endocarditis commonly involve biofilm-producing *S. aureus* strains.

The emergence of methicillin-resistant *S. aureus* (MRSA) has dramatically altered the

epidemiology of bacterial infections. MRSA strains exhibit resistance to nearly all β-lactam antibiotics and frequently demonstrate multidrug resistance involving macrolides, fluoroquinolones, aminoglycosides, and tetracyclines. Community-associated MRSA and hospital-associated MRSA differ in epidemiological characteristics but both contribute substantially to global antimicrobial resistance.

In addition to methicillin resistance, reduced susceptibility to glycopeptides such as vancomycin has emerged among certain clinical isolates, leading to the development of vancomycin-intermediate (*VISA*) and vancomycin-resistant (*VRSA*) strains. These developments highlight the urgent need for continued surveillance, rational antibiotic use, and innovative therapeutic approaches targeting both bacterial growth and biofilm formation.

3. Mechanisms of Biofilm Formation in *Staphylococcus aureus*

Biofilm formation is one of the most important virulence characteristics of *Staphylococcus aureus*, enabling the organism to survive hostile environmental conditions, evade host immune responses, and tolerate antimicrobial therapy. Biofilms are structured microbial communities enclosed within a self-produced extracellular polymeric substance (EPS) composed of polysaccharides, proteins, extracellular DNA (eDNA), lipids, and water. This matrix anchors bacterial cells to biological tissues and medical devices while creating a protective environment that promotes bacterial persistence. The thesis emphasizes that biofilm formation is a dynamic, genetically regulated process that contributes significantly to chronic and recurrent infections.

Biofilm development occurs through four sequential stages: initial attachment, irreversible adhesion, maturation, and dispersion.

During the initial attachment phase, planktonic bacterial cells adhere reversibly to host tissues or biomaterial surfaces through physicochemical interactions. Surface adhesins known as microbial surface components recognizing adhesive matrix molecules (MSCRAMMs), including fibronectin-binding proteins (FnBPs), clumping factors (ClfA and ClfB), collagen-binding proteins, and elastin-binding proteins, facilitate attachment to extracellular matrix proteins deposited on implanted medical devices.

The second stage, irreversible adhesion, is characterized by production of extracellular polymeric substances that firmly anchor bacterial cells to the surface. One of the principal biofilm components is polysaccharide intercellular adhesin (PIA), synthesized by enzymes encoded within the icaADBC operon. PIA promotes bacterial aggregation, stabilizes the developing biofilm architecture, and enhances resistance to host immune defenses.

During biofilm maturation, bacterial microcolonies proliferate and develop into complex three-dimensional structures containing water channels that facilitate nutrient transport and waste removal. Mature biofilms exhibit remarkable physiological heterogeneity, with metabolically active cells located near the surface and dormant persister cells residing within deeper layers. These dormant cells demonstrate markedly reduced susceptibility to antimicrobial agents because many antibiotics target actively dividing bacteria.

The final stage, biofilm dispersion, enables bacterial cells to detach from the mature biofilm and disseminate to new anatomical sites or medical devices. Dispersion is regulated through enzymatic degradation of extracellular matrix components and quorum sensing pathways that coordinate bacterial communication. Detached cells retain enhanced virulence and may initiate secondary infections, contributing to recurrent disease.

The ability to transition between planktonic growth and biofilm formation allows *S. aureus* to adapt rapidly to changing environmental conditions and represents one of the primary reasons for the persistence of healthcare-associated infections.

4. Virulence Factors Associated with Biofilm Development

The pathogenic success of *Staphylococcus aureus* depends upon numerous virulence determinants that facilitate colonization, immune evasion, tissue invasion, and biofilm formation. These factors act synergistically throughout the infection process and contribute substantially to disease severity.

4.1 Surface Adhesion Proteins

Adhesion represents the first essential step in biofilm formation. MSCRAMMs enable bacterial attachment to fibronectin, fibrinogen, collagen, laminin, elastin, and other extracellular matrix proteins. Fibronectin-binding proteins (FnBPA and FnBPB), clumping factors (ClfA and ClfB), collagen adhesins (Cna), and protein A collectively promote colonization of host tissues and implanted medical devices.

4.2 Polysaccharide Intercellular Adhesin (PIA)

PIA is synthesized through expression of the icaADBC gene cluster and constitutes one of the principal components of the biofilm matrix. PIA promotes bacterial aggregation, stabilizes biofilm architecture, and protects embedded cells from phagocytosis and antimicrobial agents. Expression of the **ica operon** is influenced by environmental stress, osmolarity, nutrient availability, and antibiotic exposure.

4.3 Extracellular DNA (eDNA)

Extracellular DNA released through bacterial autolysis contributes significantly to biofilm

stability. eDNA strengthens the extracellular matrix, facilitates horizontal gene transfer, and enhances bacterial adhesion during early biofilm development. Degradation of eDNA using DNase has therefore emerged as a potential therapeutic strategy for disrupting established biofilms.

4.4 Quorum Sensing

Biofilm formation is regulated through quorum sensing, a bacterial communication mechanism mediated primarily by the accessory gene regulator (agr) system. Quorum sensing enables bacterial populations to coordinate gene expression according to cell density, thereby regulating biofilm maturation, toxin production, enzyme secretion, and biofilm dispersion. Disruption of quorum sensing pathways has attracted considerable interest as a novel antibiofilm strategy.

4.5 Secreted Enzymes and Toxins

Staphylococcus aureus produces numerous extracellular enzymes and toxins that facilitate tissue invasion and immune evasion. Proteases, lipases, nucleases, hyaluronidases, hemolysins, leukocidins, and enterotoxins contribute to host tissue destruction while simultaneously promoting bacterial dissemination. Within biofilms, production of these virulence factors is tightly regulated according to environmental conditions and bacterial population density.

Collectively, these virulence determinants enable *S. aureus* to establish persistent infections that frequently resist both host immune defenses and conventional antimicrobial therapy.

5. Biofilm Formation and Antibiotic Resistance

The close relationship between biofilm formation and antimicrobial resistance represents one of the greatest challenges in the clinical management of *Staphylococcus aureus* infections. Bacteria embedded within mature biofilms exhibit resistance levels that may be 100–1,000 times greater than their planktonic counterparts, making eradication extremely difficult. This enhanced tolerance results from multiple complementary mechanisms rather than a single resistance pathway.

One of the principal mechanisms involves restricted antibiotic penetration. The extracellular polymeric matrix acts as a physical diffusion barrier that delays or reduces penetration of antimicrobial agents into deeper biofilm layers. Consequently, bacteria located within the interior of the biofilm are exposed to sub-inhibitory antibiotic concentrations that promote survival and selection of resistant subpopulations.

A second mechanism involves reduced metabolic activity. Many bacterial cells residing

within mature biofilms exist in a dormant or slow-growing physiological state. Since numerous antibiotics—including β-lactams and fluoroquinolones—target actively dividing bacteria, metabolically inactive persister cells remain largely unaffected and survive antimicrobial treatment. Following completion of therapy, these surviving cells can repopulate the biofilm, resulting in recurrent infection.

Biofilms also facilitate horizontal gene transfer, enabling dissemination of antibiotic resistance genes among neighboring bacterial cells. Transfer of plasmids, transposons, and other mobile genetic elements accelerates the spread of resistance determinants, including the mecA gene, which encodes penicillin-binding protein 2a (PBP2a) responsible for methicillin resistance in MRSA.

In addition to biofilm-mediated tolerance, *S. aureus* possesses multiple intrinsic resistance mechanisms, including β-lactamase production, target-site modification, efflux pumps, reduced membrane permeability, and altered metabolic pathways. These mechanisms frequently coexist within biofilm-producing strains, resulting in multidrug resistance and therapeutic failure.

The thesis highlights the increasing prevalence of multidrug-resistant biofilm-producing *S. aureus* strains and emphasizes the importance of molecular characterization of biofilm-associated proteins and resistance determinants to support development of targeted therapeutic strategies.

Consequently, management of biofilm-associated *S. aureus* infections often requires a combination of prolonged antimicrobial therapy, surgical debridement, removal of infected prosthetic devices, and implementation of novel antibiofilm approaches.

6. Laboratory Diagnosis and Molecular Detection of Biofilm-Producing *Staphylococcus aureus*

Accurate laboratory diagnosis of biofilm-producing *Staphylococcus aureus* is essential for timely treatment, infection control, and prevention of antimicrobial resistance. Conventional microbiological methods remain the cornerstone for identification, while molecular diagnostic techniques provide rapid detection of virulence genes, biofilm-associated genes, and antimicrobial resistance determinants. The thesis highlights several laboratory techniques, including bacterial isolation, DNA extraction, polymerase chain reaction (PCR), cloning, protein expression, electrophoresis, and biofilm characterization, which collectively improve understanding of *S. aureus* pathogenicity and biofilm biology.

Clinical specimens such as blood, wound swabs, pus, sputum, urine, catheter tips, and tissue

biopsies are cultured on selective media including Blood Agar and Mannitol Salt Agar (MSA). Colonies of *S. aureus* typically appear as smooth, golden-yellow colonies with β-hemolysis on blood agar. Gram staining demonstrates Gram-positive cocci arranged in grape-like clusters, while biochemical identification involves catalase, coagulase, DNase, and mannitol fermentation tests.

Biofilm detection is commonly performed using both qualitative and quantitative techniques. The Congo Red Agar (CRA) method provides rapid screening for slime-producing isolates, whereas the Tube Method (TM) assesses adherence of bacterial cells to glass surfaces following crystal violet staining. However, the Microtiter Plate Assay (MTP) is considered the gold standard because it quantitatively measures biofilm biomass through spectrophotometric analysis and provides superior reproducibility.

Advances in molecular biology have greatly improved diagnostic accuracy. Polymerase chain reaction (PCR) enables rapid amplification of genes associated with biofilm formation and antimicrobial resistance. The icaA, icaD, icaB, and icaC genes encode enzymes responsible for synthesis of polysaccharide intercellular adhesin (PIA), while the mecA gene confirms methicillin resistance. Additional genes including agr, sarA, fnbA, fnbB, clfA, clfB, and spa regulate adhesion, quorum sensing, virulence, and biofilm maturation.

The thesis further describes DNA isolation, cloning, protein purification, sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and Western blotting as valuable techniques for characterizing biofilm-associated proteins and identifying novel therapeutic targets. These molecular approaches enhance understanding of bacterial pathogenesis and facilitate development of innovative antibiofilm therapies.

Modern technologies such as Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry (MALDI-TOF MS), real-time PCR, whole-genome sequencing (WGS), and next-generation sequencing (NGS) now permit rapid species identification, strain typing, outbreak investigation, and comprehensive resistance profiling. These methods have significantly improved infection surveillance and antimicrobial stewardship in healthcare settings.

7. Emerging Therapeutic Strategies Against Biofilm-Associated *Staphylococcus aureus*

The increasing prevalence of biofilm-associated multidrug-resistant *Staphylococcus aureus* infections has stimulated extensive research into novel therapeutic approaches that extend beyond conventional antibiotics. Since mature biofilms exhibit remarkable tolerance to antimicrobial agents, successful treatment frequently requires a combination of

pharmacological and non-pharmacological interventions.

7.1 Combination Antimicrobial Therapy

Combination antibiotic therapy is increasingly recommended for complicated biofilm-associated infections. Agents such as vancomycin, linezolid, daptomycin, ceftaroline, rifampicin, and fosfomycin are often used in combination to enhance bacterial eradication and reduce resistance development. Rifampicin is particularly effective against biofilm-associated bacteria because of its excellent penetration into biofilm matrices; however, it should never be administered as monotherapy because resistance develops rapidly.

7.2 Antimicrobial Peptides

Antimicrobial peptides (AMPs) have emerged as promising alternatives to conventional antibiotics. These naturally occurring peptides disrupt bacterial cell membranes, inhibit biofilm formation, and demonstrate activity against multidrug-resistant *S. aureus*. Because AMPs target membrane integrity rather than specific metabolic pathways, the likelihood of resistance development is comparatively low.

7.3 Bacteriophage Therapy

Bacteriophages specifically infect and lyse bacterial cells while leaving normal human microbiota unaffected. Phage-derived enzymes, including endolysins and depolymerases, can degrade extracellular biofilm matrices and improve antibiotic penetration. Phage therapy has shown encouraging results against chronic wound infections, prosthetic joint infections, and catheter-associated infections caused by MRSA.

7.4 Quorum Sensing Inhibitors

Since biofilm formation is regulated through quorum sensing, inhibition of bacterial communication pathways represents another promising therapeutic strategy. Molecules targeting the **accessory gene regulator (agr)** system reduce expression of virulence genes, interfere with biofilm maturation, and enhance susceptibility to conventional antibiotics.

7.5 Nanotechnology-Based Drug Delivery

Nanotechnology has introduced innovative approaches for targeted antimicrobial delivery. Metallic nanoparticles including silver, gold, zinc oxide, and chitosan nanoparticles exhibit intrinsic antibacterial activity while simultaneously improving delivery of antibiotics into mature biofilms. Nanocarrier systems enhance drug stability, prolong antimicrobial activity, and reduce systemic toxicity.

7.6 Enzymatic Biofilm Disruption

Biofilm-dispersing enzymes such as DNase I, dispersin B, proteases, and glycosidases degrade extracellular matrix components, facilitating penetration of antimicrobial agents into

deeper biofilm layers. Combination therapy involving enzymatic degradation followed by targeted antibiotic administration has demonstrated encouraging results in experimental studies.

7.7 Antimicrobial Stewardship

Appropriate antimicrobial stewardship remains fundamental for controlling resistance. Rational antibiotic prescribing, routine susceptibility testing, infection prevention measures, surveillance of resistant organisms, and adherence to evidence-based treatment guidelines collectively reduce unnecessary antibiotic exposure and slow the emergence of multidrug-resistant strains.

8. Future Perspectives

Future research on *Staphylococcus aureus* biofilms should focus on development of targeted therapies capable of disrupting biofilm architecture while simultaneously eliminating embedded bacterial cells. Advances in genomics, transcriptomics, proteomics, and metabolomics are expected to improve understanding of molecular pathways governing biofilm development and antimicrobial resistance.

Artificial intelligence (AI) and machine learning are increasingly being integrated into clinical microbiology laboratories for rapid interpretation of culture results, prediction of antimicrobial resistance, and identification of high-risk patients. Whole-genome sequencing will continue to improve surveillance of hospital outbreaks and facilitate precision antimicrobial therapy.

Future therapeutic approaches are expected to combine conventional antibiotics with quorum sensing inhibitors, bacteriophages, antimicrobial peptides, nanoparticles, monoclonal antibodies, vaccines, and CRISPR-Cas gene-editing technologies. These multidisciplinary approaches may overcome limitations associated with current antimicrobial therapies and substantially improve patient outcomes.

Strengthening infection prevention programs, optimizing antimicrobial stewardship, and promoting collaborative research between microbiologists, clinicians, molecular biologists, and pharmaceutical scientists will be essential for addressing the growing burden of biofilm-associated infections.

9. CONCLUSION

Staphylococcus aureus remains one of the most clinically significant bacterial pathogens because of its remarkable ability to form biofilms and develop multidrug resistance. Biofilm

formation enhances bacterial survival, facilitates chronic infection, and substantially reduces the effectiveness of conventional antimicrobial therapy. The interaction between biofilm-associated tolerance and genetic antimicrobial resistance mechanisms has contributed to the global emergence of methicillin-resistant and multidrug-resistant *S. aureus* strains, creating significant therapeutic challenges.

Current evidence demonstrates that successful management of biofilm-associated infections requires accurate laboratory diagnosis, early identification of resistance mechanisms, species-specific antimicrobial susceptibility testing, and implementation of comprehensive antimicrobial stewardship programs. Molecular diagnostic techniques including PCR, MALDI-TOF MS, and whole-genome sequencing have greatly improved understanding of biofilm biology and resistance mechanisms while supporting rapid clinical decision-making.

Emerging therapies including bacteriophage therapy, antimicrobial peptides, quorum sensing inhibitors, nanotechnology-based drug delivery systems, enzymatic biofilm disruption, and combination antimicrobial therapy offer promising alternatives for overcoming biofilm-mediated resistance. Continued research into these innovative strategies, together with improved infection prevention practices and interdisciplinary collaboration, will be critical for reducing the global burden of biofilm-associated *Staphylococcus aureus* infections and preserving the effectiveness of existing antimicrobial agents.

REFERENCES

1. Archer, N. K., Mazaitis, M. J., Costerton, J. W., Leid, J. G., Powers, M. E., & Shirtliff, M. E. (2011). *Staphylococcus aureus* biofilms: Properties, regulation, and roles in human disease. *Virulence, 2*(5), 445–459.
2. Arciola, C. R., Campoccia, D., & Montanaro, L. (2018). Implant infections and biofilm formation. *Nature Reviews Microbiology, 16*(7), 397–409.
3. Boles, B. R., & Horswill, A. R. (2011). *Staphylococcus aureus* biofilm disassembly. *Trends in Microbiology, 19*(9), 449–455.
4. Chambers, H. F., & DeLeo, F. R. (2009). Waves of resistance: *Staphylococcus aureus* in the antibiotic era. *Nature Reviews Microbiology, 7*(9), 629–641.
5. Clinical and Laboratory Standards Institute. (2024). *Performance standards for antimicrobial susceptibility testing* (34th ed.). CLSI.
6. Costerton, J. W., Stewart, P. S., & Greenberg, E. P. (1999). Bacterial biofilms: A common cause of persistent infections. *Science, 284*(5418), 1318–1322.
7. Foster, T. J. (2017). Antibiotic resistance in *Staphylococcus aureus*. *Current Status and*

Future Prospects. *FEMS Microbiology Reviews, 41*(3), 430–449.

8. Hall-Stoodley, L., Costerton, J. W., & Stoodley, P. (2004). Bacterial biofilms: From the natural environment to infectious diseases. *Nature Reviews Microbiology, 2*(2), 95–108.
9. Otto, M. (2018). *Staphylococcal* biofilms. *Microbiology Spectrum, 6*(4), 1–17.
10. Otto, M. (2021). Quorum sensing control in *Staphylococcus aureus*. *Annual Review of Microbiology, 75*, 577–598.
11. Parsek, M. R., & Singh, P. K. (2003). Bacterial biofilms: An emerging link to disease pathogenesis. *Annual Review of Microbiology, 57*, 677–701.
12. Stewart, P. S., & Costerton, J. W. (2001). Antibiotic resistance of bacteria in biofilms. *The Lancet, 358*(9276), 135–138.
13. Tong, S. Y. C., Davis, J. S., Eichenberger, E., Holland, T. L., & Fowler, V. G. (2015). *Staphylococcus aureus* infections: Epidemiology, pathophysiology, clinical manifestations, and management. *Clinical Microbiology Reviews, 28*(3), 603–661.
14. World Health Organization. (2024). *Antimicrobial resistance: Global report on surveillance*. WHO.
15. Yamada, K., et al. (2022). Novel antibiofilm strategies against methicillin-resistant *Staphylococcus aureus*. *Journal of Fungi, 8*(5), 455.